Clinical Trial Update: Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

View source ↗

Summary

Clinical trial update reporting results from the CLAD CROSS prospective effectiveness and safety study evaluating cladribine in people with multiple sclerosis w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MAVENCLAD (cladribine)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Status: COMPLETED | Results posted: 2025-06-24